臺灣博碩士論文加值系統

目前治療口腔鱗狀上皮細胞癌的標準化療藥物仍為氟尿嘧啶及甲氨蝶呤，
然而這些藥物常傷及正常細胞造成不可避免之副作用。近年來奈米金因具有生
物醫學的應用潛力而備受關注，其可藉由操控粒子之大小或與標靶結合之不同
區域以提高對腫瘤細胞選擇性之攻擊。本研究將觀察奈米金結合化療藥物是否
對癌細胞與正常細胞具有選擇毒殺性，我們計畫在各種條件下合成系列之氟尿
嘧啶-奈米金與甲氨蝶呤-奈米金複合物，運用紫外光吸收光譜、x 光能量螢光
光譜、遠紅外光光譜與穿透式電子顯微鏡鑑定物理特徵，並檢視藥物對不同細
胞之毒殺性。初步結果顯示，沉澱部分之氟尿嘧啶-奈米金藥物相較於原化療
藥物對口腔癌細胞具有較低之IC50 數值，且合成物呈圓形，大小均為20 nm 藥
效最佳。然而甲氨蝶呤-奈米金系列則無較好效果。有趣的是氟尿嘧啶-奈米金
對正常細胞幾乎不具毒殺性。於細胞機制層面，氟尿嘧啶-奈米金較原型藥物
不易誘發細胞自噬並表現較低之LC3 蛋白，顯示氟尿嘧啶原型藥物可能誘發細
胞自噬使癌細胞藉以逃脫凋亡，而氟尿嘧啶-奈米金則能避免癌細胞此自救行
為而提高毒殺效益。動物實驗確認氟尿嘧啶-奈米金誘發調低之肝腎細胞毒性，
且具有抑制癌細胞生成之效用。本研究合成之氟尿嘧啶-奈米金具有較高毒殺
效應、較低副作用且誘發較低之細胞自噬作用，我們期許此奈米金藥物於臨床
上治療口腔癌病患之未來應用。

Unavoidable side effects of chemotherapy drug, used in oral squamous cell
carcinoma (OSCC), including 5-fluorouracil (5FU) and methotrexate (MTX), is still
a burden issue clinically. Our present study has been demonstrated a simple and
effective method for synthesizing 5FU-conjugated gold nanoparticles (5FU-AuNPs)
to attenuate drug toxicity in normal cells, and directly target OSCC cells, in which to
avoid off-target effect. On the basis of physical properties, Fourier transform infrared
spectroscopy (FT-IR), UV-vis absorption spectroscopy (UV-vis), energy dispersive
X-ray fluorescence spectrometry (EDX), and transmission electron microscopy
(TEM) were utilized to characterize 5FU-AuNPs, and defined the optimal size
approximately 20 nm and shaped in spherical structure. We thus comprehensively
studied the effect of 5FU-AuNP in vitro. 5FU-AuNP showed identical effective IC50
value in cancer cell lines, but it showed no toxicity in normal fibroblast and epithelial
cells compared to conventional 5FU drugs. Furthermore, 5FU-AuNP induced lower
expression of LC3, the essential element of autophagosome in SAS cells than 5FU
treatment group, which promoted autophagy to escape from OSCC cell death. In
tumor-bearing mice model, 5FU-AuNP did not cause significant hepatotoxicity and
kidney damage as evidenced by biochemical analysis, although the tumorigenicity
was effectively reduced in both treatment, this study demonstrates that 5FU-AuNP
iii
could be a potential nanodrug to treat OSCC without off-target effects and
unmanageable autophagy.

中文摘要.........................................................................................................................i
Abstract........................................................................................................................ii
Introduction..................................................................................................................1
General Methods..........................................................................................................6
Materials. ...............................................................................................................6
Preparation of 5FU-AuNPs and MTX-AuNPs. .....................................................6
Cell culture.............................................................................................................7
Fourier transform infrared spectroscopy (FTIR) spectra analysis .........................7
UV–visible absorbance (UV-vis) spectroscopy analysis .......................................8
Transmission electron microscopy (TEM) images ................................................8
Cell cytotoxicity assay ...........................................................................................9
Western Blotting ..................................................................................................10
Cellular Uptake Pathways of 5FU-AuNP#5dep. ....................................................10
Real-Time Living Cell Imaging. ..........................................................................11
Mouse Xenograft Tumor Models.........................................................................11
Statistical Analysis ...............................................................................................12
Results .........................................................................................................................13
Discussion....................................................................................................................19
v
Figure ..........................................................................................................................22
Supplement information............................................................................................32
Reference ....................................................................................................................37

1. Chang PM, Teng HW, Chen PM, Chang SY, Chu PY, Tsai TL, et al. Methotrexate
and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in
metastatic/recurrent head and neck cancer. Journal of the Chinese Medical
Association : JCMA. 2008 Jul;71(7):336-41. PubMed PMID: 18653395.
2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et
al. Postoperative irradiation with or without concomitant chemotherapy for locally
advanced head and neck cancer. The New England journal of medicine. 2004 May
6;350(19):1945-52. PubMed PMID: 15128894.
3. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem.
Cancer metastasis reviews. 2005 Jan;24(1):9-17. PubMed PMID: 15785869.
4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer
statistics, 2004. CA: a cancer journal for clinicians. 2004 Jan-Feb;54(1):8-29. PubMed
PMID: 14974761.
5. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment
paradigm. Cancer. 2008 Oct 1;113(7 Suppl):1911-32. PubMed PMID: 18798532.
Pubmed Central PMCID: 2751600.
6. Price KA, Cohen EE. Current treatment options for metastatic head and neck
38
cancer. Current treatment options in oncology. 2012 Mar;13(1):35-46. PubMed PMID:
22252884.
7. Tong D, Poot M, Hu D, Oda D. 5-Fluorouracil-induced apoptosis in cultured oral
cancer cells. Oral oncology. 2000 Mar;36(2):236-41. PubMed PMID: 10745178.
8. Merlano M, Benasso M, Cavallari M, Blengio F, Rosso M. Chemotherapy in
head and neck cancer. European journal of cancer Part B, Oral oncology. 1994
Sep;30B(5):283-9. PubMed PMID: 7535608.
9. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase:
mechanism of inhibition by 5-fluoro-2''-deoxyuridylate. Biochemical and biophysical
research communications. 1972 Sep 26;48(6):1565-71. PubMed PMID: 4263280.
10. Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van
Groeningen CJ, et al. Thymidylate synthase and drug resistance. European journal of
cancer. 1995 Jul-Aug;31A(7-8):1299-305. PubMed PMID: 7577040.
11. Halwachs S, Lakoma C, Schafer I, Seibel P, Honscha W. The antiepileptic drugs
phenobarbital and carbamazepine reduce transport of methotrexate in rat choroid
plexus by down-regulation of the reduced folate carrier. Molecular pharmacology.
2011 Oct;80(4):621-9. PubMed PMID: 21737571.
12. Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, et al. Galactosylated
39
chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side
effects. World journal of gastroenterology : WJG. 2012 Nov 14;18(42):6076-87.
PubMed PMID: 23155336. Pubmed Central PMCID: 3496884.
13. Halilova KI, Brown EE, Morgan SL, Bridges SL, Jr., Hwang MH, Arnett DK, et
al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do
we stand? International journal of rheumatology. 2012;2012:978396. PubMed PMID:
22844292. Pubmed Central PMCID: 3400362.
14. Guimbaud R, Guichard S, Dusseau C, Bertrand V, Aparicio T, Lochon I, et al.
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour
tissues of colon and liver in humans. Cancer chemotherapy and pharmacology.
2000;45(6):477-82. PubMed PMID: 10854135.
15. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of
5-fluorouracil (capecitabine, UFT, S-1): a review. The oncologist. 2002;7(4):288-323.
PubMed PMID: 12185293.
16. Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and
strategies for modulation in cancer chemotherapy. Cancer investigation.
1999;17(7):494-506. PubMed PMID: 10518194.
17. Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Biologically optimized
40
nanosized molecules and particles: more than just size. Bioconjugate chemistry. 2011
Jun 15;22(6):993-1000. PubMed PMID: 21513351. Pubmed Central PMCID:
3116041.
18. Ghosh P, Gang H., Mrinmoy D., Chae K.K., Ro. VM. Gold nanoparticles in
delivery applications. Advanced Drug Delivery Reviews. 2008;60:1307-15.
19. Huo Q. A perspective on bioconjugated nanoparticles and quantum dots. Colloids
and Surfaces B: Biointerfaces. 2007;59:1-10.
20. Doane T, B. C. Nanoparticle mediated non-covalent drug delivery. Advanced
Drug Delivery Reviews. 2012;65:607–21.
21. Kim CS, Gulen Y.T., David S., M.R. V. Inorganic nanosystems for therapeutic
delivery: Status and prospects. Advanced Drug Delivery Reviews. 2013;65:93–9.
22. Vigderman L, R.Z. E. Therapeutic platforms based on gold nanoparticles and
their covalent conjugates with drug molecules. Advanced Drug Delivery Reviews.
2013;65:663–76.
23. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells.
The international journal of biochemistry & cell biology. 2004 Dec;36(12):2445-62.
PubMed PMID: 15325584.
24. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation.
41
Science. 2000 Dec 1;290(5497):1717-21. PubMed PMID: 11099404. Pubmed Central
PMCID: 2732363.
25. Ng G, Huang J. The significance of autophagy in cancer. Molecular
carcinogenesis. 2005 Aug;43(4):183-7. PubMed PMID: 16001423.
26. Hippert MM, O''Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both?
Cancer research. 2006 Oct 1;66(19):9349-51. PubMed PMID: 17018585.
27. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer
development and response to therapy. Nature reviews Cancer. 2005 Sep;5(9):726-34.
PubMed PMID: 16148885.
28. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy
delays apoptotic death in breast cancer cells following DNA damage. Cell death and
differentiation. 2007 Mar;14(3):500-10. PubMed PMID: 16990848.
29. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, et al.
Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and
enhances mitochondrial depolarization. Breast cancer research and treatment. 2008
Dec;112(3):389-403. PubMed PMID: 18172760.
30. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of
autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell
42
death and differentiation. 2004 Apr;11(4):448-57. PubMed PMID: 14713959.
31. Kim EH, Sohn S, Kwon HJ, Kim SU, Kim MJ, Lee SJ, et al. Sodium selenite
induces superoxide-mediated mitochondrial damage and subsequent autophagic cell
death in malignant glioma cells. Cancer research. 2007 Jul 1;67(13):6314-24. PubMed
PMID: 17616690.
32. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy. 2006
Apr-Jun;2(2):85-90. PubMed PMID: 16874083.
33. Hoyer-Hansen M, Jaattela M. Autophagy: an emerging target for cancer therapy.
Autophagy. 2008 Jul;4(5):574-80. PubMed PMID: 18362515.
34. Mah LY, Ryan KM. Autophagy and cancer. Cold Spring Harbor perspectives in
biology. 2012 Jan;4(1):a008821. PubMed PMID: 22166310.
35. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P.
Autophagy: for better or for worse. Cell research. 2012 Jan;22(1):43-61. PubMed
PMID: 21912435. Pubmed Central PMCID: 3351915.
36. Gump JM, Thorburn A. Autophagy and apoptosis: what is the connection?
Trends in cell biology. 2011 Jul;21(7):387-92. PubMed PMID: 21561772. Pubmed
Central PMCID: 3539742.
37. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments
43
5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model.
European journal of cancer. 2010 Jul;46(10):1900-9. PubMed PMID: 20231086.
38. Pan X, Zhang X, Sun H, Zhang J, Yan M, Zhang H. Autophagy inhibition
promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human
non-small cell lung cancer A549 cells. PloS one. 2013;8(2):e56679. PubMed PMID:
23441212. Pubmed Central PMCID: 3575481.
39. Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as
emerging mechanisms of nanomaterial toxicity. Particle and fibre toxicology.
2012;9:20. PubMed PMID: 22697169. Pubmed Central PMCID: 3441384.